A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Inclusion Criteria: * Diagnosis must have been before the patient's 16th birthday * Disease duration of at least 6 months before study entry * Must have 5 or more joints with active arthritis * Must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area \[BSA\] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate) * May take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of NSAIDS (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry * Must have qualifying laboratory values at the first visit. Exclusion Criteria: * Have known allergies, hypersensitivity, or intolerance to golimumab or similar therapeutics * Are pregnant or breast-feeding, or planning a pregnancy or fathering a child within 6 months after the last study agent administration * Have initiated DMARDS and/or immunosuppressive therapy within 4 weeks prior to study initiation